DI
PTCT icon

Disciplined Investments’s PTC Therapeutics PTCT Stock Holding History

Disciplined Investments’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$203 – 1199
2023
Q2 		$203 Buy
5
+1
+25% +$49 ﹤0.01% 1496
2023
Q1 		$194 Buy
4
+1
+33% +$46 ﹤0.01% 1487
2022
Q4 		$115 Hold
3
– – ﹤0.01% 1521
2022
Q3 		$0 Buy
+3
New +$147 ﹤0.01% 1530

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Disciplined Investments's PTCT Position: Q3 2023 in Review

Disciplined Investments sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 5 shares — an estimated $203 sold.

Disciplined Investments first reported a position in PTCT in Q3 2022 and held it in 4 quarters. The position peaked at $203 in Q2 2023. 179 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

  • Disciplined Investments reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Disciplined Investments sold 5 PTC Therapeutics shares in Q3 2023, an estimated $203.
  • Disciplined Investments first reported a position in PTC Therapeutics in Q3 2022 and held it in 4 quarters.
  • Disciplined Investments's PTC Therapeutics position peaked at $203 in Q2 2023.
  • 179 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.